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apoE isoform–specific clearance across the mouse BBB in vivo. (A) Time-disappearance curves of 14C-inulin (reference molecule, black) and 
125I-labeled human lipid-poor apoE4 (dark green), apoE3 (light green), apoE2 (yellow green), Aβ42 (dark blue), and Aβ40 (light blue) after microinfu-
sion of tracers mixture into brain ISF in the caudate nucleus. Test tracers were studied at 40 nM. The percentage recovery in brain was calculated 
using Equation 1 (see Methods). TCA-precipitable 125I-radioactivity was used. Each point represents a single experiment. (B) Time-dependent efflux 
across the BBB of 125I-labeled Aβ40, Aβ42, lipid-poor apoE2, apoE3, and apoE4 (yellow green, light green, dark green) and lipo-apoE2 (brown), lipo-
apoE3 (red), and lipo-apoE4 (orange) was calculated from data in Figure 1A and Equation 4 (see Methods). The ISF bulk flow for studied test trac-
ers was calculated using Equation 2 (see Methods). (C) Relative contributions of transport across the BBB (black bars), ISF flow (white bars), and 
degradation (dark gray bars) to clearance of apoE isoforms from brain and their retention in the brain (light gray bars) were studied at 40 nM concen-
trations and calculated from fractional coefficients given in Supplemental Table 1. Mean ± SEM; n = 11–24 mice per group for multiple-time series. 
*P < 0.05, lipid-poor apoE4 versus lipid-poor apoE3 or apoE2; †P < 0.05, lipo-apoE4, lipo-apoE3, and lipo-apoE2 versus corresponding lipid-poor 
apoE4, apoE2 and apoE3. ‡P < 0.05, lipo-apoE4 versus lipo-apoE3 or lipo-apoE2. (D and E) Time-appearance curves of 14C-inulin and 125I-labeled 
lipid-poor apoE4, apoE3, and apoE2 (TCA-precipitable 125I-radioactivity) in the CSF (D) and plasma (E) from experiments as in A. ID, injected dose. 
§P < 0.05, apoE2, apoE3, and apoE4 versus inulin; ¶P < 0.05, apoE4 versus apoE2 or apoE3. Mean ± SEM; n = 3–5 mice per group.
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apoE isoform–specific clearance across the 
mouse BBB in vivo depends on differential 
contributions of VLDLR-mediated and LRP1-
mediated transport. (A) 125I-labeled lipo-
apoE2, lipo-apoE3, and lipo-apoE4 (TCA-pre-
cipitable 125I-radioactivity) BBB clearance at 
90 minutes in the presence and absence of 
receptor-specific blocking antibodies against 
VLDLR, LRP1, and LDLR and excess unla-
beled ligands at 0.5 μM. (B) Western blot 
analysis of VLDLR, LDLR, and LRP1 in brain 
microvessels isolated from control, VLDLR–/–, 
and LDLR–/– mice. β-actin was used as a load-
ing control. The lanes were run on the same 
gel but were noncontiguous. Representative 
blots from 3 mice per group are shown. (C and 
D) 125I-labeled lipo-apoE2, lipo-apoE3, and 
lipo-apoE4 (TCA-precipitable 125I-radioactiv-
ity) BBB clearance at 90 minutes in VLDLR–/– 
(C) and LDLR–/– mice (D) in the presence 
and absence of receptor-specific antibodies 
against VLDLR, LRP1, or LDLR. Values are 
mean ± SEM; n = 3–5 mice per group.
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apoE isoforms disrupt Aβ clearance across the mouse BBB in vivo (apoE4>apoE3 or apoE2) by redirecting differentially redirecting transport of 
Aβ-apoE complexes from LRP1 to VLDLR. 125I-labeled apoE-Aβ complexes (40 nM) and 14C-inulin were microinfused into brain ISF and clearance 
determined at 90 minutes. 125I-label was either on Aβ40 and Aβ42 or on apoE2 and apoE4. (A) FPLC purification of apoE2-Aβ40. Upper panel 
shows dot blots of Aβ40-apoE2 and free Aβ peaks with Aβ-specific (6E10) and apoE-specific (3D12) antibodies. (B and C) BBB clearance of 
Aβ40 (B) and Aβ42 (C) with and without an LRP1-specific blocking antibody and of their complexes with lipid-poor and lipo-apoE2 and lipid-poor 
and lipo-apoE4, as indicated. (D) Clearance of Aβ40 and Aβ42 by transport across the BBB (black bars), ISF flow (white bars) and degradation 
(light gray bars) and retention in the brain (dark gray bars) studied from different 125I-Aβ40-apoE and Aβ42-apoE complexes at 40 nM and com-
pared with free Aβ40 or Aβ42. 125I-label was on Aβ. Clearance and retention were calculated from fractional coefficients using Equations 2, 5, and 
6 (see Methods). Mean ± SEM, n = 5–6 mice per group in a single time-point series. *P < 0.05, Aβ40-apoE2 and Aβ40-apoE4 versus Aβ40 and 
Aβ42–lipo-apoE2, Aβ42–lipo-apoE3, and Aβ42–lipo-apoE4 versus Aβ42; †P < 0.05, Aβ40-apoE4 versus Aβ40-apoE2 and Aβ42–lipo-apoE4 ver-
sus Aβ42–lipo-apoE3 or Aβ42–lipo-apoE2; ‡P < 0.05, Aβ40–lipo-apoE2 and Aβ40–lipo-apoE4 versus Aβ40-apoE2 and Aβ40-apoE4; §P < 0.05, 
Aβ40–lipo-apoE4 versus Aβ40–lipo-apoE3 or Aβ40–lipo-apoE2. (E) BBB clearance of 125I-Aβ40–lipo-apoE2 and 125I-Aβ40–lipo-apoE3 in control 
mice with and without blocking antibodies to VLDLR, LRP1, and LDLR. (F and G) BBB clearance of 125I-Aβ40–lipo-apoE2 (F) and 125I-Aβ42–lipo-
apoE4 complexes (G) in control (white bars), VLDLR–/– (gray bars), and RAP–/– (black bars) mice with and without blocking antibodies to LRP1, 
VLDLR, and/or LDLR. Mean ± SEM; n = 4–6 mice per group.
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Isoform-specific lipid-poor apoE clearance at the ablumi-
nal surface of mouse brain capillaries in vitro is regulated 
by differential internalization rates of VLDLR and LRP1. 
(A) Specific binding of 125I-labeled lipid-poor apoE2, 
apoE3, and apoE4 (2 nM, TCA-precipitable 125I-radio-
activity) by brain microvessels studied for a period of 
30 minutes at 4°C with and without excess of unlabeled 
ligand at 0.5 μM. (B–D) Time-dependent internalization of 
lipid-poor 125I-apoE2 (B), 125I-apoE3 (C), and 125I-apoE4 
(D) on the abluminal surface of brain microvessels in the 
presence of receptor-specific blocking antibodies to LRP1 
and VLDLR and excess of unlabeled ligand at 0.5 μM.
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Isoform-specific lipo-apoE clearance at the abluminal surface of mouse brain capillaries in vitro is regulated by differential internalization 
rates of VLDLR and LRP1. (A) Binding of 125I-labeled lipo-apoE2 and lipo-apoE4 (2 nM, TCA-precipitable 125I-radioactivity) to isolated brain 
microvessels. (B and C) Time-dependent internalization of 125I-labeled lipo-apoE2 (B) and lipo-apoE4 (C) in the presence of receptor-spe-
cific blocking antibodies against VLDLR and LRP1 and excess of unlabeled ligand at 0.5 μM. (D) Binding of 125I-labeled lipo-apoE2 to brain 
microvessels from control, VLDLR–/–, and LDLR–/– mice. (E–G) Internalization of 125I-labeled lipo-apoE2 (E), lipo-apoE3 (F), and lipo-apoE4 
(G) at the abluminal surface of brain microvessels from control (white bars) and VLDLR–/– (black bars) mice studied for a period of 30 minutes. 
Means ± SEM, n = 3 experiments per group.
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bition (apoE4>apoE3 and 
apoE2) of Aβ internalization 
at the abluminal surface of 
mouse brain capillaries in vitro 
is mediated by VLDLR. (A) 
Specific binding of 125I-labeled 
Aβ40 and Aβ42 complexes 
with apoE2 and apoE4 at 4°C 
in the absence and presence 
of receptor-specific blocking 
antibodies to VLDLR, LDLR, 
or LRP1 and excess unla-
beled ligand at 0.5 μM. (B) 
Internalization of 125I-Aβ40 in 
the absence and presence of 
receptor-specific blocking anti-
bodies against LRP1 and of 
125I-labeled Aβ40–lipo-apoE2, 
Aβ40–lipo-apoE3, and Aβ40–
lipo-apoE4 complexes for a 
period of 30 minutes. (C) Inter-
nalization of 125I-labeled Aβ40, 
Aβ40–lipo-apoE2, Aβ40–lipo-
apoE3, and Aβ40–lipo-apoE4 
in the absence and presence 
of receptor-specific blocking 
antibodies against LRP1 and 
VLDLR. Means ± SEM; n = 3–5 
experiments per group.
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VLDLR at  the abluminal  side of  the BBB,  resulting  in poor 
Aβ clearance of apoE-Aβ complexes from brain. Lipo-apoE4 
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